Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Jenia Jenab-Wolcott"'
Publikováno v:
American Journal of Gastroenterology. 117:e226-e227
Autor:
Christopher Ambrogi, Sahaj Desai, Randi Zukas Carhart, Jenia Jenab-Wolcott, Julia Chia-Ying Shih
Publikováno v:
Journal of Clinical Oncology. 41:114-114
114 Background: Prostate adenocarcinoma is the second leading cause of cancer-related death in men in the United States. A major risk factor is family history, with prostate cancer in a first-degree relative effectively doubling a patient’s risk. H
Autor:
Stephanie Rivera Morales, Ian Dale, Kristin Mattie, Brooke Levin, Jamin C. Morrison, Jenia Jenab-Wolcott
Publikováno v:
Journal of Clinical Oncology. 40:311-311
311 Background: Despite guidelines recommending germline genetic testing (GT) and genetic counseling for individuals with pancreatic ductal adenocarcinoma (PDAC), referrals remain suboptimal. This can have negative implications on treatment, particul
Publikováno v:
Current Colorectal Cancer Reports. 9:230-241
Colorectal cancer is a major public health problem and, despite recent advances in treatment, most patients with metastatic colorectal cancer (mCRC) will succumb to their disease. Yet, survival of patients with mCRC has markedly improved as the numbe
Publikováno v:
Molecular and Cellular Biology. 20:8373-8381
Defects in DNA mismatch repair predispose cells to the development of several types of malignant disease. The absence of Msh2 or Mlh1, two key molecules that mediate mismatch repair in eukaryotic cells, increases the frequency of mutation and also al
Publikováno v:
Molecular Pathology Library ISBN: 9781461460145
Personalized medicine utilizes the molecular basis of disease to provide tools to stratify risk and predict treatment effect; and in doing so provides the opportunity for rational design of cancer therapeutics. In particular, the genetic events assoc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f9a110157088ed3b84a77e8a9c0d2b22
https://doi.org/10.1007/978-1-4614-6015-2_9
https://doi.org/10.1007/978-1-4614-6015-2_9
Publikováno v:
Clinical colorectal cancer. 9
The past 5 years mark a watershed period in the treatment of patients with colorectal cancer (CRC). During this time, results from several clinical trials proved that targeting tumor-mediated angiogenesis improves overall survival for patients with m
Publikováno v:
Expert opinion on biological therapy. 9(4)
Background: Angiogenesis is essential for cancer growth and metastasis. VEGF is a key modulator of angiogenesis and its overexpression is correlated with advanced disease and poor prognosis. Bevacizumab, a recombinant humanized anti-VEGF mAb, is the
Publikováno v:
Molecular and cellular biology. 19(7)
Transformation of pre-B cells by Abelson murine leukemia virus (Ab-MLV) involves a balance between positive, growth-stimulatory signals from the v-Abl oncoprotein and negative regulatory cues from cellular genes. This phenomenon is reflected by the c